[1] Awan A A, Jadoul M, Martin P. Hepatitis C in chronic kidney disease: an overview of the KDIGO Guideline[J]. Clin Gastroenterol Hepatol, 2020,18(10):2158-2167. [2] Toyoda H, Kikuchi K. Management of dialysis patients with hepatitis C virus in the era of direct-acting antiviral therapy[J]. Ther Apher Dial, 2023,27(5):831-838. [3] 张唯伟, 袁琼婧, 宁建平, 等. 维持性血液透析丙型肝炎病毒感染患者的抗病毒治疗及预后[J]. 中南大学学报(医学版),2021,46(12):1332-1337. [4] Fabrizi F, Cerutti R, Messa P. An updated view on the antiviral therapy of hepatitis C in chronic kidney disease[J]. Pathogens, 2021,10(11):1381. [5] Sharma P, Sawtell R, Wang Q, et al. Management of hepatitis C virus and hepatitis B virus infection in the setting of kidney disease[J]. Adv Kidney Dis Health, 2023,30(4):343-355. [6] Ji Q, Chu X, Zhou Y, et al. Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients[J]. J Med Virol, 2022,94(2):675-682. [7] Sise M E, McQuaid T, Martin P. Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease[J]. Nephrol Dial Transplant, 2022,37(12):2327-2334. [8] Sallam M, Khalil R. Contemporary insights into hepatitis C virus: a comprehensive review[J]. Microorganisms, 2024,12(6):1035. [9] 项波, 周毅骏, 金巧菲, 等. 索磷布韦/维帕他韦治疗慢性丙型肝炎疗效及安全性分析[J]. 浙江中西医结合杂志, 2021,31(9):824-827. [10] 郭峰, 窦婧, 徐强, 等. 以索磷布韦为基础的DAA治疗泛基因型慢性丙型肝炎患者的疗效观察[J]. 肝脏, 2021,26(11):1224-1227. [11] 冯倩嫦, 张春兰, 李凌华, 等. 索磷布韦维帕他韦治疗慢性丙型肝炎的真实世界研究[J]. 肝脏, 2021,26(6):606-610. [12] Chariyavilaskul P, Prompila N, Wittayalertpanya S, et al. Pharmacokinetics of sofosbuvir/velpatasvir and efficacy of an alternate-day treatment in hemodialysis patients with chronic hepatitis C infection[J]. Clin Transl Sci, 2024,17(7):e13884. [13] Wiegand J, Buggisch P, Mauss S, et al. Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German hepatitis C-registry (Deutsches hepatitis C-register)[J]. Eur J Gastroenterol Hepatol, 2019,31(11):1424-1431. [14] Fabrizi F, Tripodi F, Cerutti R, et al. Recent information on pan-genotypic direct-acting antiviral agents for HCV in chronic kidney disease[J]. Viruses, 2022,14(11):2570. [15] 陈祥浩. 索磷布韦维帕他韦片治疗慢性丙型肝炎的效果观察[J]. 实用中西医结合临床, 2022, 22(8):104-106. [16] Cespiati A, Coelho Rodrigues I, Santos I, et al. Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities: a systematic review[J]. Liver Int, 2024,44(5):1075-1092. [17] Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease[J]. Kidney Int, 2022,102(6S):S129-S205. [18] Ryu J E, Song M J, Kim S H, et al. Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease[J]. Korean J Intern Med, 2022,37(5):958-968. [19] Ratiu I A, Mihaescu A, Olariu N, et al. Hepatitis C virus infection in hemodialysis patients in the era of direct-acting antiviral treatment: observational study and narrative review[J]. Medicina (Kaunas), 2024,60(12):2093. |